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Aims The aim was to study the prognostic value of plasma ceramides (Cer) as cardiovascular death (CV death) markers in
three independent coronary artery disease (CAD) cohorts.
Methods
and results
Corogene study is a prospective Finnish cohort including stable CAD patients (n ¼ 160). Multiple lipid biomarkers and
C-reactive protein were measured in addition to plasma Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:0), and
Cer(d18:1/24:1). Subsequently, the association between high-risk ceramides and CV mortality was investigated in
the prospective Special Program University Medicine—Inflammation in Acute Coronary Syndromes (SPUM-ACS)
cohort (n ¼ 1637), conducted in four Swiss university hospitals. Finally, the results were validated in Bergen Coronary
Angiography Cohort (BECAC), a prospective Norwegian cohort study of stable CAD patients. Ceramides, especially
when used in ratios, were significantly associated with CV death in all studies, independent of other lipid markers and
C-reactive protein. Adjusted odds ratios per standard deviation for the Cer(d18:1/16:0)/Cer(d18:1/24:0) ratio were
4.49 (95% CI, 2.24–8.98), 1.64 (1.29–2.08), and 1.77 (1.41–2.23) in the Corogene, SPUM-ACS, and BECAC studies,
respectively. The Cer(d18:1/16:0)/Cer(d18:1/24:0) ratio improved the predictive value of the GRACE score
(net reclassification improvement, NRI ¼ 0.17 and DAUC ¼ 0.09) in ACS and the predictive value of the Marschner
score in stable CAD (NRI ¼ 0.15 and DAUC ¼ 0.02).
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Conclusions Distinct plasma ceramide ratios are significant predictors of CV death both in patients with stable CAD and ACS, over
and above currently used lipid markers. This may improve the identification of high-risk patients in need of more ag-
gressive therapeutic interventions.
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Introduction
Given the high prevalence of coronary artery disease (CAD) and
associated mortality, prevention of fatal and non-fatal myocardial
infarctions (MI) in CAD patients remains an ongoing clinical chal-
lenge. Mortality rates among stable CAD patients range between
1% and 3%, while rates of non-fatal events are 1–2% annually.1 In
patients with acute coronary syndromes (ACS) who survive the
acute event, the rate of MI and death is markedly higher, particularly
during the first year.2 However, at the individual level, the event risk
may vary considerably, which makes risk estimation tools necessary
to improve patient management. Expedient risk stratification should
identify individuals at risk requiring more intensive therapy. Con-
versely, patients with a favorable prognosis should be identified to
avoid drug overuse and associated side effects.3
Hypothesis free lipidomic analyses have revealed a handful of
lipids potentially qualifying as useful prognostic markers for
CAD.4 – 6 In our initial lipidomic study, distinct ceramide species
were significantly associated with CVD among CAD patients.4 Mo-
lecular lipid species, particularly ceramide(d18:1/16:0), were also as-
sociated with necrotic core tissue type and lipid core burden in
coronary angiography, and were predictive for 1-year clinical out-
come in 581 ACS and stable CAD patients.7 In these studies, plasma
CVD risk-related ceramide molecules (Cer(d18:1/16:0), Cer(d18:1/
18:0), and Cer(d18:1/24:1)), and their ratios with Cer(d18:1/24:0),
emerged as potential risk stratifiers for CAD patients.4 Ceramides
are known to associate with many central processes of atheroscler-
osis development including lipoprotein uptake, inflammation, and
apoptosis (Supplementary material online, Figure S1).8 Ceramide
species are produced by six fatty acyl selective ceramide synthases
(CerSs; Supplementary material online, Figure S2), and it is becoming
evident that individual ceramide species have specific physiological
functions.9 – 12 Thus, monitoring ratios of ceramides species may
provide insight into the metabolic regulation of atherosclerotic
events. In this study, we establish the suggested role of ceramides
and their distinct ratios as risk predictors for CV death in patients
with stable CAD and ACS.
Methods
More detailed method descriptions are available in Supplementary
material online.
Study subjects
Corogene study: stable coronary artery disease patients
Corogene is a prospective, consecutive cohort study of Finnish patients
referred for coronary angiography to the Helsinki University Central
Hospital between 2006 and 2008. A nested case control study was de-
signed using the Corogene database and including data from the national
death certificate registry. As cases, all patients who experienced coron-
ary death within an average follow-up of 212 years were selected.
Matched control patients had established CAD (.50% stenosis at least
in one epicardial coronary artery), but remained alive during the follow-
up period. Baseline characteristics of the Corogene subjects are shown
in Table 1 and Supplementary material online, Table S1.
Bergen Coronary Angiography Cohort cohort: patients
with stable coronary artery disease
The Bergen Coronary Angiography Cohort (BECAC) includes 1580
adults referred to elective coronary angiography because of suspected
stable angina pectoris recruited at the Haukeland University Hospital in
Bergen, Norway between 2000 and 2004. Information on cardiovascu-
lar deaths was collected from the Cause of Death Registry at the Nor-
wegian Institute of Public Health, and verified against hospital medical
records whenever available. During a median follow-up of 4.6 years, a
total of 81 patients died from cardiovascular disease. Baseline character-
istics of the BECAC participants are reported in Table 1 and Supplemen-
tary material online, Table S1.
SPUM-ACS cohort: patients with acute coronary
syndromes
Special Program University Medicine—Inflammation in Acute Coronary
Syndromes (SPUM-ACS) is a prospective, multi-centre (Bern, Geneva,
Lausanne, and Zu¨rich) cohort study. Patients with a primary diagnosis of
ACS and referred for invasive management were enrolled at four Swiss
university hospitals. Baseline characteristics of the SPUM-ACS patients
are summarized in Table 1 and Supplementary material online, Table S1.
At one-year follow-up, a total of 51 patients died from cardiac reasons.
Clinical laboratory analyses
Standard lipids measurements were determined using standard methods
available at each of the three study sites. In Corogene subjects, apolipo-
proteins (AI, AII, and B), lipoprotein (a), lipoprotein-associated phospho-
lipase A2 activity, and HDL and LDL particle numbers and sizes were
measured as described in Supplementary material online, Methods.
Quantification of ceramides
The plasma levels of Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:0),
and Cer(d18:1/24:1) were quantified on a 5500 QTRAP (SCIEX, Fra-
mingham, MA) mass spectrometer equipped with an Eksigent 100-XL
UHPLC system as described recently.13
Statistical analyses
Wilcoxon’s rank sum test was applied for group comparisons. Odds ra-
tios (ORs) per standard deviation were estimated using logistic regres-
sion. Hazard ratios were calculated using the Cox proportional hazard
model. The GRACE14 risk score, consisting of Killip class, systolic blood
pressure, heart rate, age, creatinine, cardiac arrest at admission,
ST-segment deviation, and elevated cardiac enzyme levels (troponin,
CK-MB), was used to calculate the risk of long-term mortality for
ACS patients. The following Marschner score15 variables were used in
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the modeling of stable CAD patient data: total cholesterol, HDL-C, age,
gender, smoking status, previous acute MI, diabetes, hypertension, and
prior stroke.
Net reclassification improvement was estimated as described by
Pencina et al.16 For the 1-year event risk of the secondary prevention
population in the SPUM-ACS study we categorized subjects to low
risk (,1% event probability), intermediate (1–5%) risk or high-risk
(.5%) groups. For the BECAC study the same categorization was
used for 3-year risk.
The ceramide risk score was calculated as follows: For each individual, all
three ceramide ratios and each concentration (apart from Cer(d18:1/24:0))
were compared with the whole study population. If the variable belonged
to the 3rd quartile, the individual received +1 point, and if to the 4th quar-
tile, +2 points (Supplementary material online, Table S11). Thus, the score
ranges from 0 to 12 and based on the score, the subjects were split into
four risk categories (0–2, 3–6, 7–9, and 10–12).
More details on statistical methods can be found in Supplementary
material online.
Results
Ceramide concentrations in high- and low-
risk patients with coronary artery disease
In stable CAD patients of the Corogene study LDL-based markers
such as LDL-C, LDL particle number (LDL-P), small dense LDL
(sdLDL), and apoB did not differ significantly between cases who ex-
perienced coronary death and controls who remained alive, and nei-
ther did Lp(a) nor Lp-PLA2. However, the HDL-related markers
HDL-C, HDL particle number (HDL-P), small dense HDL (sdHDL),
and ApoA1 were all significantly (P, 0.001) different between
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Table 1 Baseline characteristics of the subjects in Corogene, SPUM-ACS and BECAC studies
Characteristic COROGENE SPUM-ACS BECAC
Cases Controls Cases Controls Cases Controls
No of subjects 80 80 51 1586 81 1506
Gender
Male, n (%) 60 (75%) 60 (75%) 42 (82%) 1223 (77%) 55 (68%) 889 (59%)
Age (years) 70.2 (62.6–77.1) 70 (63.4–76.9) 77.1 (69–83) 62.8 (53.9–72.9) 71 (64–78) 61 (54–70)
Body mass index 27.5 (23.6–30.9) 26 (24.1–29.5) 25.1 (23.1–28.3) 26.6 (24.3–29.4) 24 (22–28) 26 (23–28)
Time to death/follow-up time (days) 528 (134–739) 1955 (1669–2173) 25 (7–216) 365 (359–365) 626 (196–1332) 1720 (1368–2111)
Creatinine (mmol/L) 98 (84–134) 79 (69–90) 100 (79–134) 75 (65–88) 98 (87–115) 87 (79–97)
Current smoker
Yes, n (%) 37 (46%) 37 (46%) 16 (31%) 663 (42%) 29 (36%) 355 (24%)
No, n (%) 43 (54%) 43 (54%) 33 (65%) 897 (57%) 50 (62%) 1146 (76%)
NA 2 (4%) 26 (2%) 2 (2%) 5 (0%)
Diabetes
Yes, n (%) 32 (40%) 32 (40%) 11 (22%) 266 (17%) 16 (20%) 159 (11%)
No, n (%) 48 (60%) 48 (60%) 40 (78%) 1320 (83%) 64 (79%) 1333 (89%)
NA 1 (1%) 14 (1%)
Hypertension
Yes, n (%) 60 (75%) 60 (75%) 36 (71%) 912 (58%) 55 (68%) 674 (45%)
No, n (%) 20 (25%) 20 (25%) 15 (29%) 674 (42%) 26 (32%) 832 (55%)
Lipid-lowering treatment
Yes, n (%) 61 (76%) 61 (76%) 14 (27%) 432 (27%) 61 (75%) 933 (62%)
No, n (%) 19 (24%) 19 (24%) 34 (67%) 1146 (72%) 20 (25%) 573 (38%)
NA 3 (6%)
Previous AMI
Yes, n (%) 67 (84%) 0 (0%) 8 (16%) 210 (13%) 54 (67%) 482 (32%)
No, n (%) 13 (16%) 80 (100%) 43 (84%) 1374 (87%) 27 (33%) 1024 (68%)
NA 2 (0%)
Previous stroke
Yes, n (%) 17 (21%) 10 (12%) 2 (4%) 37 (2%) 15 (19%) 108 (7%)
No, n (%) 63 (79%) 70 (88%) 49 (96%) 1549 (98%) 66 (81%) 1398 (93%)
Plasma ceramides predict cardiovascular death 1969
the groups with the medians being 217.1, 214.3, 219.0, and
212.9% lower in cases, respectively. The differences between cases
and controls in plasma ceramides and established lipid markers are
provided in Table 2 (the percentage of observations for each marker
is provided in Supplementary material online, Table S2).
In the Corogene study, the concentrations of Cer(d18:1/16:0),
Cer(d18:1/18:0), and Cer(d18:1/24:1) were significantly different
(P , 0.001 for all) between cases who had a fatal MI during
the follow-up period and controls (medians in cases +17.0%,
+10.3, and +11.2% higher than in controls, respectively). In con-
trast, the Cer(d18:1/24:0) behaved differently, with the median in
cases being 214.9% lower than in controls (P, 0.001). Similarly
to our earlier observations,4 highly significant differences, were
observed for the three predefined ceramide ratios, with the med-
ians of cases ranging between +25.7 and +34.8% (P , 0.001)
relative to controls. The difference between stable CAD patients
and controls is illustrated in Supplementary material online,
Figure S3.
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Table 2 Medians and inter quartile ranges of established lipid markers and ceramides in case and control groupsa
BECAC SPUM-ACS
Cases (n 5 81) Controls (n5 1499) P-value Cases (n5 51) Controls (n5 1586) P-value
Cer(d18:1/16:0)/Cer(d18:1/24:0) 0.121 (0.101–0.145) 0.100 (0.085–0.119) ,0.001 0.116 (0.099–0.170) 0.093 (0.079–0.113) ,0.001
Cer(d18:1/18:0)/Cer(d18:1/24:0) 0.046 (0.036–0.059) 0.038 (0.031–0.049) ,0.001 0.064 (0.044–0.084) 0.047 (0.037–0.060) ,0.001
Cer(d18:1/24:1)/Cer(d18:1/24:0) 0.498 (0.408–0.624) 0.413 (0.337–0.508) ,0.001 0.489 (0.415–0.675) 0.394 (0.337–0.474) ,0.001
Cer(d18:1/16:0) (mmol/L) 0.271 (0.235–0.326) 0.253 (0.213–0.300) 0.010 0.313 (0.255–0.385) 0.292 (0.247–0.346) 0.090
Cer(d18:1/18:0) (mmol/L) 0.108 (0.077–0.143) 0.096 (0.076–0.123) 0.097 0.161 (0.109–0.234) 0.146 (0.112–0.189) 0.163
Cer(d18:1/24:0) (mmol/L) 2.335 (1.843–2.866) 2.548 (2.030–3.098) 0.035 2.366 (2.112–3.084) 3.107 (2.490–3.826) ,0.001
Cer(d18:1/24:1) (mmol/L) 1.056 (0.927–1.344) 1.028 (0.844–1.257) 0.026 1.421 (1.012–1.628) 1.229 (1.004–1.484) 0.175
LDL-C (mg/dL) 110 (89–133) 116 (93–147) 0.087 101 (81–128) 121 (93–150) 0.001
HDL-C (mg/dL) 46 (35–58) 50 (41–62) 0.036 48 (36–58) 44 (36–53) 0.266
TC (mg/dL) 185 (158–212) 193 (166–224) 0.081 159 (147–189) 189 (161–221) ,0.001
TG (mg/dL) 135 (100–169) 126 (92–182) 0.738 76 (54–108) 92 (61–142) 0.014
COROGENE
Cases (n 5 80) Controls (n5 80) P-value
Cer(d18:1/16:0)/Cer(d18:1/24:0) 0.132 (0.105–0.175) 0.105 (0.090–0.128) ,0.001
Cer(d18:1/18:0)/Cer(d18:1/24:0) 0.062 (0.047–0.077) 0.046 (0.037–0.062) ,0.001
Cer(d18:1/24:1)/Cer(d18:1/24:0) 0.703 (0.582–0.846) 0.556 (0.483–0.665) ,0.001
Cer(d18:1/16:0) (mmol/L) 0.275 (0.222–0.326) 0.235 (0.212–0.282) 0.007
Cer(d18:1/18:0) (mmol/L) 0.118 (0.094–0.152) 0.107 (0.092–0.137) 0.195
Cer(d18:1/24:0) (mmol/L) 1.923 (1.475–2.511) 2.235 (1.993–2.672) 0.008
Cer(d18:1/24:1) (mmol/L) 1.385 (1.189–1.620) 1.245 (1.091–1.427) 0.017
TC (mg/dL) 128 (111–165) 139 (122–163) 0.064
TG (mg/dL) 108 (86–140) 92 (75–139) 0.110
LDL-C (mg/dL) 69 (55–99) 75 (65–92) 0.251
LDL-P (nmol/L) 830 (694–1110) 928 (712–1175) 0.395
sdLDL (nmol/L) 533 (304–659) 548 (376–737) 0.265
ApoB (mg/dL) 67 (55–82) 68.5 (57–84) 0.997
HDL-C (mg/dL) 34 (29–40) 41 (33–51) ,0.001
HDL-P (mmol/L) 24 (21–27) 28 (24–31) ,0.001
sdHDL (mmol/L) 12.8 (9.3–15.6) 15.8 (13.1–18.2) ,0.001
ApoA1 (mg/dL) 115 (101–131) 132 (115–150) ,0.001
Lp(a) (mg/dL) 7.2 (2–35) 3.6 (1–28) 0.319
Lp-PLA2 (nmol/min/ml) 138 (119–166) 130 (115–163) 0.354
C-reactive protein (mg/L) 3.1 (1.6–8.7) 1.1 (0.7–2.8) ,0.001
aCer, ceramide; TC, total cholesterol; TG, triacylglycerols, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, sdLDL small dense low-density
lipoprotein cholesterol, LDL-P low-density lipoprotein particle number, sdHDL small dense high-density lipoprotein cholesterol, HDL-P high-density lipoprotein particle number,
ApoB apolipoprotein B, ApoA1 apolipoprotein A1, Lp(a) lipoprotein (a), Lp-PLA2 lipoprotein-associated phospholipase A2. SI conversion factors: To convert cholesterol to
mmol/L, multiply values by 0.0259; to convert triacylglycerols to mmol/L, multiply values by 0.01129.
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Ceramide ratios in coronary artery
disease patients
In the Corogene study, the most significant ORs for coronary death
were found for HDL markers and ceramide ratios. Ceramide ORs re-
mained predictive after adjustment for conventional lipid markers
LDL-C, HDL-C, total cholesterol, triacylglycerols, and C-reactive pro-
tein. Lp-PLA2 and Lp(a) had no significant association with CV
mortality.
LDL-C and LDL particle number were inversely associated with
risk (LDL-C unadjusted upper quartile OR 0.89 95% CI 0.37–2.14;
LDL-P upper quartile OR 0.67, 95%CI 0.29–1.59). For comparison,
the unadjusted upper quartile OR for the Cer(d18:1/16:0)/
Cer(d18:1/24:0) ratio was 10.33 (95% CI 3.69–28.97). Figure 1
shows non-adjusted and adjusted ORs for different lipid markers
and ceramides in the Corogene study.
Ceramides and risk in stable coronary
artery disease patients
An independent assessment of ceramides was performed in a co-
hort (BECAC) of stable patients. We found that the predefined
ceramide ratios were significantly higher in 81 patients who died fol-
lowing a CV event within 4.6-year follow-up compared with those
who did not die during follow-up (Table 2; Supplementary material
online, Table S2). For comparability with the Corogene results, non-
adjusted and adjusted ORs for standard lipid markers and ceramides
are given in Supplementary material online, Table S3. The incremen-
tal improvement of discrimination for CV death was further demon-
strated by calculating hazard ratios adjusted for standard lipids and
the Marschner score variables (Table 3).
Adjustment for statin treatment did not have a major impact on the
results (Supplementary material online, Table S4). The odds ratios
were calculated for ceramides and LDL-C also in patients that were
on or not on statin treatment both at baseline and after 1-year of
follow-up (Supplementary material online, Table S5). Ceramides
were predictive in both instances, although in patients without statin
treatment the odds ratios were better. LDL-C did not show significant
predictive value, confirming that the lack of a direct association
between LDL-C and CV death was not caused by interference with
statin treatment.
The incremental prognostic value of ceramides was tested by
comparing the base model composed of the Marschner score
Figure 1 Cardiovascular death odds ratios for per standard deviation and 4th quartile for different lipid markers and ceramides in Corogene
study. Adjustment is made for total cholesterol, triacylglycerols, LDL-C, HDL-C, and C-reactive protein.
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variables to a new model with the Marschner score variables
combined with the Cer(d18:1/16:0)/Cer(d18:1/24:0) ratio. The
ceramides increased the cross-validated c-statistics from 0.78
(0.75–0.80) to 0.80 (0.77–0.82). Further, the predicted probabil-
ities for a 1-year event risk by logistic regression yielded an NRI of
0.15 (95% CI 0.06–0.25; 9.6% improvement for events and 5.8%
improvement for non-events).
Ceramides and risk prediction in acute
coronary syndromes patients
Another independent assessment of ceramides was performed in
the SPUM-ACS cohort enrolling ACS patients. In 51 patients who
died following a cardiac event within one-year-follow-up the cera-
mide ratios were significantly higher compared with those who
survived during follow-up (Table 2; Supplementary material online,
Table S2). For comparability with the Corogene results, non-
adjusted and adjusted ORs for standard lipid markers and ceramides
are given in Supplementary material online, Table S3, and the effects
of statin treatment are accounted for the results in Supplementary
material online, Table S4. The incremental improvement of discrim-
ination for cardiac death was further demonstrated by adjusting for
standard lipids and the GRACE score (Table 4), and also by taking
into account diabetes mellitus and smoking status (Supplementary
material online, Table S6).
The incremental prognostic value of ceramides was tested by
comparing the base model composed of the GRACE score to a
new model with the GRACE score and the Cer(d18:1/16:0)/
Cer(d18:1/24:0) ratio on top. The ceramide ratio increased
the cross-validated c-statistics from 0.73 (0.70–0.77) to 0.82
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Table 3 Association between ceramides and cardiovascular death in BECACa
Univariate model Multivariableb model 1b Multivariablec model 2c
Hazard ratiod (95% CI) P-value Hazard ratiod (95% CI) P-value Hazard ratiod (95% CI) P-value
Cer(d18:1/16:0)/Cer(d18:1/24:0)e 1.77 (1.46–2.16) ,0.001 1.79 (1.45–2.20) ,0.001 1.52 (1.21–1.92) ,0.001
Cer(d18:1/18:0)/Cer(d18:1/24:0)e 1.63 (1.31–2.04) ,0.001 1.58 (1.25–2.00) ,0.001 1.29 (1.01–1.65) 0.039
Cer(d18:1/24:1)/Cer(d18:1/24:0)e 1.61 (1.30–1.98) ,0.001 1.58 (1.27–1.97) ,0.001 1.31 (1.03–1.66) 0.028
Cer(d18:1/16:0)e 1.44 (1.17–1.77) ,0.001 2.09 (1.61–2.73) ,0.001 1.75 (1.30–2.35) ,0.001
Cer(d18:1/18:0)e 1.33 (1.07–1.65) 0.011 1.54 (1.19–2.01) 0.001 1.27 (0.98–1.66) 0.076
Cer(d18:1/24:0)e 0.83 (0.67–1.02) 0.081 0.82 (0.62–1.10) 0.182 0.91 (0.69–1.21) 0.510
Cer(d18:1/24:1)e 1.39 (1.13–1.72) 0.002 1.74 (1.34–2.25) ,0.001 1.38 (1.04–1.82) 0.023
Cer denotes ceramide.
aCV death denotes death from MI, stroke, and heart failure.
bThe model was adjusted for TC, TG, HDL-C, and LDL-C.
cThe model was adjusted as for model 1 with additional adjustment for the following Marschner score variables: age, gender, smoking status, previous acute MI, diabetes,
hypertension, and prior stroke.
dHazard ratios are for 1 SD increase.
eNatural logarithm of the ceramides and ceramide ratio.
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Table 4 Association between ceramides and cardiovascular death in SPUM-ACSa
Univariate model Multivariableb model 1b Multivariablec model 2c
Hazard ratiod (95% CI) P-value Hazard ratiod (95% CI) P-value Hazard ratiod (95% CI) P-value
Cer(d18:1/16:0)/Cer(d18:1/24:0) 1.81 (1.52–2.14) ,0.001 1.82 (1.51–2.21) ,0.001 1.69 (1.39–2.06) ,0.001
Cer(d18:1/18:0)/Cer(d18:1/24:0) 1.66 (1.43–1.96) ,0.001 1.65 (1.39–1.97) ,0.001 1.48 (1.24–1.76) ,0.001
Cer(d18:1/24:1)/Cer(d18:1/24:0) 1.74 (1.45–2.08) ,0.001 1.77 (1.44–2.17) ,0.001 1.64 (1.32–2.03) ,0.001
Cer(d18:1/16:0)e 1.45 (1.10–1.93) 0.010 1.96 (1.45–2.66) ,0.001 1.98 (1.49–2.62) ,0.001
Cer(d18:1/18:0)e 1.43 (1.07–1.90) 0.015 1.77 (1.31–2.38) ,0.001 1.66 (1.26–2.20) ,0.001
Cer(d18:1/24:0)e 0.66 (0.51–0.87) 0.003 0.74 (0.52–1.05) 0.090 0.91 (0.65–1.29) 0.609
Cer(d18:1/24:1)e 1.23 (0.93–1.63) 0.154 1.74 (1.25–2.42) 0.001 1.73 (1.27–2.36) ,0.001
Cer denotes ceramide.
aCV death denotes death from MI, stroke, and heart failure.
bThe model was adjusted for TC, TG, HDL-C, and LDL-C.
cThe model was adjusted as for model 1 with additional adjustment for the Grace score (Killip class, systolic blood pressure, heart rate, age, creatinine, cardiac arrest at admission,
ST-segment deviation, and elevated cardiac enzyme levels).
dHazard ratios are for one standard deviation increase.
eNatural logarithm of the ceramides.
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(0.79–0.85). Furthermore, the predicted probabilities for a 1-year
event risk obtained by logistic regression yielded an NRI of 0.17
(95% CI 0.07–0.27; 8.2% improvement for events and 9.1%
improvement for non-events).
The performance of the ceramide ratio Cer(d18:1/16:0)/
Cer(d18:1/24:0) in predicting non-fatal MI was also investigated by
calculating the hazard ratios both for Q-wave and non-Q wave
MIs. The ratio showed a significant result for Q-wave MI, while
no significant results were obtained for non-Q wave infarctions
(Supplementary material online, Table S7).
Ceramides and C-reactive protein
In the Corogene and SPUM-ACS studies, ceramides associated sig-
nificantly with LDL-C and C-reactive protein. Particularly, the CV
mortality-related Cer(d18:1/16:0) and Cer(d18:1/18:0) were posi-
tively correlated with C-reactive protein, while small negative corre-
lations were seen in both studies between C-reactive protein and
Cer(d18:1/24:0). Furthermore, the ‘protective’ Cer(d18:1/24:0)
had the strongest associations with LDL-C. Correlation coefficients
for associations of ceramides and ceramide ratios with LDL-C and
C-reactive protein are presented in Supplementary material online,
Tables S8 and S9.
Finally, the synergy of C-reactive protein and Cer(d18:1/16:0)/
Cer(d18:1/24:0) in risk stratification was investigated by calculating
event rates in different quartiles for both BECAC and SPUM-ACS.
Especially in the SPUM-ACS study the highest enrichment of events
(11.4% 1-year mortality) was observed if both the ceramide ratio
and C-reactive protein were in the highest quartile of the whole
population (Supplementary material online, Table S10).
Ceramide score and risk for
cardiovascular death
We have developed a tentative risk score (Supplementary material
online, Table S11) based on ceramide concentrations and their ra-
tios to model the clinical use of these risk predictors. Based on
the score, the patients were placed into four risk categories
(low–moderate– increased–high) and both in the BECAC and
SPUM-ACS studies the risk increased along with the increasing
score (Table 5). In the stable CAD and ACS patients 4.2- and
6.0-fold relative risk increase was observed when comparing
the high- to low-risk category, respectively. When subjects were
sorted according to their LDL-C concentrations and split into
four categories in the same proportion as for the ceramide risk
score the enrichment of high-risk patients was not observed along
with increasing LDL-C concentration.
Discussion
The present results provide evidence that distinct ceramide species
serve as significant predictors for cardiovascular death beyond
currently used lipid markers in two patient groups—patients with
stable CAD and higher risk ACS patients . Importantly, the predic-
tion also works in patients who are already statin treated and is
therefore a potential indicator of residual risk.
Battes et al.17 recently performed a systematic review of models
predicting outcome in patients with stable CAD. The authors
concluded that risk stratification should be improved to predict re-
current coronary events and to optimize secondary prevention
strategies. Our data using ceramides address this unmet need and
show robust performance for predicting coronary death both in
stable CAD and ACS patients. The present results do not prove
causality. However, it is tempting to speculate that ceramides are
associated with plaque vulnerability as they are known to fuel
many central atherosclerosis processes including lipoprotein aggre-
gation and uptake, inflammation, superoxide anion production, and
apoptosis8,18–21 (Supplementary material online, Figure S1). Several
enzymes of the sphingolipid synthesis have already been tested as
potential drug targets as inhibition of glycosphingolipid biosynthesis
has been shown to decrease atherosclerosis in mice.10,22 Evidence
is also accumulating on ceramide chain-length-specific functions.
In a recent study, the relative increase in long-chain species (C16)
but not in very-long-chain (C24-24:1) species was shown to
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Table 5 Ceramide score and risk for cardiovascular death
BECAC (5-year risk) SPUM-ACS (1-year risk)
Score No death Death % Relative risk Score No death Death % Relative risk
0–2 534 15 2.7% 1.0 0–2 566 9 1.6% 1.0
3–6 572 29 4.8% 1.8 3–6 595 16 2.6% 1.7
7–9 268 20 6.9% 2.5 7–9 261 9 3.3% 2.1
10–12 132 17 11.4% 4.2 10–12 164 17 9.4% 6.0
LDL-C (mg/dl) No death Death % Relative risk LDL-C (mg/dl) No death Death % Relative risk
≤100 513 36 6.6% 1.0 ≤106 532 27 4.8% 1.0
100–143 572 29 4.8% 0.7 106–145 576 17 2.9% 0.6
143–175 278 10 3.5% 0.5 145–174 260 3 1.1% 0.2
≥175 142 6 4.1% 0.6 ≥174 174 2 1.1% 0.2
See Supplementary material online, Table S11 for information on Ceramide Score calculation. To compare Ceramide Score performance with that of LDL-C study, subjects were
sorted according to their LDL-C levels and split into four categories in the same proportion as for the ceramide risk score.
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mediate insulin resistance in mice.11,12 In Caenorhabditis elegans,
long-chain ceramides were pro-apoptotic, and very-long-chain cer-
amides were anti-apoptotic.9 Consistently in the present study,
long-chain species (d18:1/16:0 and d18:1/18:0) were more harmful
than very-long-chain (d18:1/24:0) species. Altered ceramide com-
positions may partially be explained by CerS isoforms, providing a
putative biological explanation for the use of ceramide ratios, and
possibilities for medical intervention (Supplementary material on-
line, Figure S2). Interestingly, Cer(d18:1/24:1) behaved differently
compared with Cer(d18:1/24:0), emphasizing that additional regula-
tion also takes place. While the current study reveals an association
between ceramides and CV events, it will be a highly interesting
topic for future investigations to establish if ceramide composition
can be influenced and how it might translate to cardiovascular
benefit. The response of ceramides to lipid-lowering treatments
such as statins has been documented in our previous study.4 We
have observed that PCSK9 knock-out mice have significantly
reduced plasma ceramide concentrations and that human PCSK9
loss-of-function mutations are associated with lower plasma cera-
mide concentrations compared with individuals carrying the major
alleles.4,23 Study limitations in addition to the lack of causality data
include the limited number of events both in BECAC and
SPUM-ACS. Thus, the ceramide risk score derived from these
studies should be further validated in sizeable cohorts in order to
fine-tune the relative risk estimates for different risk categories.
Finally, it is likely that the careful one-to-one case–control matching
in the Corogene study is leading to somewhat optimistic biomarker
results compared with a real-life patient care situation where con-
trolling for confounding factors is more difficult.
The lack of a discernible relationship between LDL-related
parameters and CV risk across the studies included here, even after
statin stratification, is thought-provoking but, in line with previous
reports.24 –26 For example, Sachdeva et al.24 analysed admission lipid
levels in a broad population of 136,995 patients hospitalized for
CAD in 541 hospitals and observed that nearly half of the admission
LDL-C concentrations were ,100 mg/dl although before admis-
sion only 21.1% patients were receiving lipid-lowering medications.
Furthermore, in the MIRACL trial, the plasma HDL-C, but not
LDL-C, measured in the initial stage of ACS predicted the risk of
recurrent cardiovascular events.25 The lower LDL-C in higher risk
patients may not be a phenomenon of ACS solely as in the Saturn
trial investigators observed that C-reactive protein, but not
LDL-C levels, were associated with coronary atheroma regression
and cardiovascular events after intensive statin therapy.26 Taken
together, it appears that the LDL-C concentrations may be similar
or even lower in CAD patients at high risk for future CV events
compared with patients with more favorable prognosis. This may
be a phenomenon related to disease progression and culmination,
and should not detract from the value of applying LDL-C to gauge
the lifetime risk to develop atherosclerotic plaques. A potential ex-
planation for this is provided in Gierens et al.27 who demonstrated
that interleukin-6 (IL-6) activates LDL-receptor (LDLr) transcrip-
tion and subsequently enhances LDLr activity in the liver leading
to an increased elimination of LDL-C from the circulation. Thus,
chronic, and in particular acute bursts of, inflammation in CAD
patients may enhance LDL-C clearance, resulting in lowered blood
LDL-C concentrations and impaired risk prediction.
Ceramide measurement in high-throughput quality controlled
environments is straightforward and cost-efficient. Isotope labelled
standards enable precise quantification and analytical stability. Most
clinical laboratories are equipped with robotized sample handling
systems and also house mass spectrometry equipment.
Thus, ceramide-based identification of coronary patients at high
cardiovascular risk will soon be possible. These high-risk patients
should then benefit from treatments that extend beyond standard
care. The suggested actions could include more frequent follow-up
visits and efficient life-style counselling as well as the consideration
for higher statin doses, ezetimibe combinations, or novel therapies
such as PCSK9 inhibitors. In future, additional therapies may include
other options, for example, ongoing randomized clinical trials are
looking into the effect of methotrexate and interleukin-1b inhibition
for treating cardiovascular risk.28 Indeed, ceramides are closely
linked to inflammatory processes and recently CERS6 has been
identified as a target for methotrexate.29 It is hence plausible to
think that ceramide testing could become increasingly relevant,
especially if the trials with anti-inflammatory compounds turn out
positive. A health economic dimension of ceramide testing is its abil-
ity to target more intense, potentially more expensive treatments
such as PCSK9 inhibitors to those at the highest risk. Another aspect
of ceramide testing is its potential for motivating patient’s adher-
ence, whether for medication or life-style changes, due to its rather
direct linkage with CV mortality. It has been shown that over 40% of
the patients prescribed statins are non-adherent, which may trans-
late to many avoidable additional events and hospitalizations.30
While the ceramide-based risk stratification extends beyond the
current lipid-based diagnostics and addresses the unmet need for
improved identification of high-risk CAD patients there are further
scientific and clinical issues that need attention. There are two major
lines of future research concerning the present ceramide correl-
ation and cardiovascular risk. On one hand it is of interest to pursue
the biology of these molecules and work out their molecular mech-
anism of action in cardiovascular disease. This will involve multi-
disciplinary efforts of cell biologists, biochemists, geneticists, and
clinicians developing appropriate cell and animal models. Efforts in
this regard are already being made for example in the scope of
the EU funded ‘EUFP7-Atheroflux’ consortium. The other line to
follow is to establish the utility of these markers in clinical practice.
In the USA, the ceramide testing is entering the clinic this year and
only this real-life evaluation will allow for a better judgement of the
ceramide utility and will establish them as a new armament in the
clinical diagnostic tool-kit.
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